ICCN Supports AAPM DCs


The ICCN is now offering credentialing support for chiropractors board certified by the American Academy of Pain Management (AAPM) also known by its newer name the Academy of Integrative Pain Management (AIPM). The AAPM/AIPM went bankrupt in January 2019 leaving all members hanging. Some AAPM members had recently paid their fees and provided credentialing CE hours only to see it all evaporate.

The bankruptcy of the AAPM was blamed on declining membership, loss of revenue support from pharmaceutical companies and a reduction in conference revenue. However, it was also was tied to opioid lawsuits that were filed that taxed academy resources.


DAAPM MDs and nurses had a opportunity to join pain management organizations in their respective healthcare discipline but the chiropractors did not have a place to go. The Board of the ICCN decided to give our pain management brothers and sisters a hand and have formed a Pain Management (PM) committee functioning under the authority of the ICCN Board. The PM committee will support the pain management chiropractors board certified by the AAPM who wish for us to maintain their credentials.

The ICCN will recognize the DAAPM credential by endorsement. If we are legally blocked from supporting that credential, we are prepared to provide our own credential – the Diplomate of the International College of Pain Management (DICPM). However, since the AAPM is out of business, has no assets and no staff, we don’t believe there will be any reason why we cannot support the DAAPM credential. Similarly, we currently support the defunct American Chiropractic Academy of Neurology (DACAN) credential for some of our neurology diplomates.

There is no intention at present to provide a credential in pain management to non board certified chiropractors, but that remains a possibility. We are going slow at present, and take this step to support our credentialed PM brothers and sisters.

Neurologists boarded by the AAPM should contact the ICCN office if they are interested in maintaining their PM credential. If you know someone board certified by the AAPM, please let them know about this opportunity.

Open Letter of Invitation

Dear Colleague,

I am honored to welcome you to the 1st International Conference on Advances in Migraine Sciences (ICAMS), which will be held in Copenhagen, March 10-12, 2022. More than 1,100 people have already registered for ICAMS.

The scientific programme consists of state-of-the-art lectures, debates, and poster presentations on issues of interest for the migraine field. 

ICAMS 2022 is a hybrid event that provides the possibility of online participation for international attendees; thus, aiming to meet the needs of all colleagues worldwide who are interested in migraine. 

Conference participation is free of charge and reflects our commitment to free and timely knowledge sharing.

It should be emphasized that all ICAMS content will be available on demand to allow conference participants to access videos without the constraints of the time schedule. 

Register today at: https://icams2022.com/

Kind regards

Dr. Messoud Ashina

The International Conference on Advances in Migraine Sciences held from March 10 to 12, 2022, aims to develop a research agenda and facilitate use of novel approaches to advance our understanding of disease mechanisms underlying migraine and ascertain best practices for clinical management

CBD Oil Blocks Sars-CoV-2 Infection

ICCN Clinical Report

From: Journal of Natural Products 2022


  • Naturally occurring products frequently form the basis of drug therapies that are available today.
  • In this study, CBD oil was found to block the capacity for Sars-CoV-2 to enter human cells, providing a mechanism for prevention and therapeusis
  • To identify small molecule therapeutic agents, affinity selection-mass spectrometry was used to discover botanical ligands to Sars-CoV-2 spike protein
  • Cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA) compounds found in CBD oil were found to prevent infection in human epithelial cells by SARS-CoV-2.
  • Further testing shows that CBDA and CBGA had neutralizing effect on infected cells.  SARS-CoV-2 variants B117 and B1351 were studied. Additional focus forming assays demonstrated effective blocking of virus infection by variants.
  • Volunteers were tested with oral administration of .063mg/kg of CBDA equal to 5.71 mg for a 200lb person. 



ABSTRACT: As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity selection−mass spectrometry was used for the discovery of botanical ligands to the SARS-CoV-2 spike protein. Cannabinoid acids from hemp (Cannabis sativa) were found to be allosteric as well as orthosteric ligands with micromolar affinity for the spike protein. In follow-up virus neutralization assays, cannabigerolic acid and cannabidiolic acid prevented infection of human epithelial cells by a pseudovirus expressing the SARS-CoV-2 spike protein and prevented entry of live SARS-CoV-2 into cells. Importantly, cannabigerolic acid and cannabidiolic acid were equally effective against the SARS-CoV-2 alpha variant B.1.1.7 and the beta variant B.1.351. Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2.


Richard B. van Breemen, Ruth N. Muchiri, Timothy A. Bates, Jules B. Weinstein, Hans C. Leier, Scotland Farley, and Fikadu G. Tafesse. Cannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants. J Nat Product – January 2022